The 36-month PFS rate for patients with del (17p) and/or TP53 mutation was 87% and for patients without del (17p) and TP53 mutation was 89%. The safety profile of BRUKINSA plus venetoclax was ...

Association between Modified Cardiometabolic Index and Incident Cardiovascular Disease in Middle-Aged and Elderly Chinese ...

Out of nowhere the ocean suddenly explodes like a bomb has gone off. "It was like an earthquake, the sound was phenomenal," surf photographer Ben Allen said. "I get goosebumps thinking about it." Mr ...

Over the past few decades, advances in hematology have illuminated how a delicate balance between stem cell self-renewal and differentiation sustains healthy blood formation. In myelodysplastic ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

Lindsay Curtis is a health & medical writer in South Florida. She worked as a communications professional for health nonprofits and the University of Toronto’s Faculty of Medicine and Faculty of ...

Although the year brought a steady stream of new treatments, tests, and cutting-edge science, experts worry about how politics will impact innovation long term.

Sanofi’s Tzield has been accepted for priority review by the U.S. Food and Drug Administration to expand its use to children aged one year and older with stage 2 type 1 diabetes. The submission is ...